Login to Your Account

PAH Space Getting Hotter as Actelion Files Macitentan NDA

By Nuala Moran
Staff Writer

Monday, October 22, 2012

LONDON – There's a race to market for a new generation of pulmonary arterial hypertension (PAH) drugs with Actelion Ltd. announcing it has filed for FDA approval of Opsumit (macitentan) and Bayer Healthcare revealing positive Phase III data for riociguat and promising global filings in the first half of 2013.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription